<DOC>
	<DOC>NCT00516685</DOC>
	<brief_summary>The purpose of this study is to determine whether the recombinant human EGF-rP64K/Montanide ISA 51 vaccine is safe, immunogenic and effective in the treatment of stage IIIb/IV non-small-cell lung cancer (NSCLC).</brief_summary>
	<brief_title>Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients who have signed the informed consent form. Patients who are eighteen years of age or over with histologically or cytologically confirmed NSCLC in advanced stages IIIb or IV, not amenable to any attempt of curative chemoradiotherapy and/or surgery. Patients with measurable lesions, defined as those measurable at least in one dimension (refered to higher diameter) and with a diameter equal or higher 20 mm using conventional techniques (PET, CT scan, MRI, Rx) or equal or higher 10 mm using CT scan. Patients who have finished their last cycle of chemotherapy and/or radiotherapy not less than 4 weeks prior to randomization and not more than 8 weeks. Female patients of reproductive potential must have negative pregnancy tests. Those female volunteers admitted to the study must be using a reliable means of contraception such as tubal ligation, oral contraceptive or IUD. ECOG status 0 to 2. Patients with normal organ and bone marrow function, as defined by the parameters in accordance to that provided by the normal lab reference range. Patients with no evidence of objective disease progression, 1 month after finishing first line chemotherapy as per RECIST. Patients who are candidates for combined modality treatment. Patients who are receiving immunosuppressive therapy including corticosteroids. Patients who have received immunotherapy within the previous 3 months. Patients who have participated in a clinical study within the previous 30 days. Patients who may be allergic to any component of the vaccine. Medical reasons considered by the investigators as disqualification from the study such as significant uncontrolled comorbid disease or potential noncompliance with the protocol. Patients bearing brain metastasis from the primary lung tumor. Patients bearing a second primary tumor. Patients showing progressive disease after finishing first line chemotherapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>LUNG CANCER</keyword>
	<keyword>NSCLC</keyword>
	<keyword>EGF</keyword>
	<keyword>CANCER VACCINE</keyword>
	<keyword>IMMUNOTHERAPY</keyword>
</DOC>